Sep 07, 2022 / 06:40PM GMT
Yigal Dov Nochomovitz - Citigroup Inc. Exchange Research - Research Analyst
So let's start. Welcome back, everyone. I think everyone knows me. I'm Yigal Nochomovitz, one of the biotech analyst at Citi. I cover both these distinguished companies. So welcome both of you. Scott Koenig, CEO, MacroGenics; and not [Neal Joseph], Ken from Zymeworks. So welcome both to you.
Scott Koenig - MacroGenics, Inc. - President, CEO & Director
Thank you.
Yigal Dov Nochomovitz - Citigroup Inc. Exchange Research - Research Analyst
Great. Great to have you here.
Kenneth H. Galbraith - Zymeworks Inc. - CEO & Chairman of the Board
Pleasure.
Yigal Dov Nochomovitz - Citigroup Inc. Exchange Research - Research Analyst
So I think for those who are less familiar with both of your companies, we could just start with a quick 2- to 3-minute overview of the pipeline. What are the -- highlight the key assets, maybe some of the key clinical trials you're
Zymeworks Inc and MacroGenics Inc at Citi BioPharma Conference - Co Panel: Bispecific Panel Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
